Cue Biopharma Analyst Ratings
Cue Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 201.89% | Piper Sandler | $7 → $8 | Maintains | Overweight |
| 06/26/2023 | 277.36% | Oppenheimer | → $10 | Assumes | Outperform → Outperform |
| 06/15/2023 | 201.89% | Stifel | → $8 | Reiterates | Buy → Buy |
| 05/15/2023 | 466.04% | JMP Securities | → $15 | Reiterates | Outperform → Outperform |
| 03/22/2023 | 201.89% | Stifel | $9 → $8 | Maintains | Buy |
| 03/22/2023 | 277.36% | Oppenheimer | → $10 | Reiterates | → Outperform |
| 11/21/2022 | 164.15% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 08/24/2022 | 277.36% | Oppenheimer | $26 → $10 | Maintains | Outperform |
| 03/21/2022 | 881.13% | Oppenheimer | $32 → $26 | Maintains | Outperform |
| 03/18/2022 | 881.13% | Craig-Hallum | $28 → $26 | Maintains | Buy |
| 11/24/2020 | 1032.08% | Berenberg | → $30 | Initiates Coverage On | → Buy |
| 05/20/2020 | 1032.08% | Stifel | $25 → $30 | Maintains | Buy |
| 05/20/2020 | 1107.55% | Oppenheimer | $27 → $32 | Maintains | Outperform |
| 04/21/2020 | 843.4% | Stifel | $21 → $25 | Maintains | Buy |
| 04/09/2020 | 692.45% | Stifel | → $21 | Initiates Coverage On | → Buy |
| 03/06/2020 | 1032.08% | JMP Securities | $22 → $30 | Maintains | Outperform |
| 02/25/2020 | 918.87% | Oppenheimer | → $27 | Initiates Coverage On | → Outperform |
| 01/28/2020 | 881.13% | BTIG | → $26 | Initiates Coverage On | → Buy |
| 01/22/2020 | 730.19% | JMP Securities | → $22 | Initiates Coverage On | → Market Outperform |
| 07/26/2019 | 390.57% | Baird | → $13 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/06/2023 | 201.89% | 派珀·桑德勒 | 7 美元 → 8 美元 | 维护 | 超重 |
| 06/26/2023 | 277.36% | 奥本海默 | → 10 美元 | 假设 | 跑赢大盘 → 跑赢大盘 |
| 06/15/2023 | 201.89% | Stifel | → 8 美元 | 重申 | 购买 → 购买 |
| 05/15/2023 | 466.04% | JMP 证券 | → 15 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 03/22/2023 | 201.89% | Stifel | 9 美元 → 8 美元 | 维护 | 买 |
| 03/22/2023 | 277.36% | 奥本海默 | → 10 美元 | 重申 | → 跑赢大盘 |
| 11/21/2022 | 164.15% | 派珀·桑德勒 | → 7 美元 | 启动覆盖范围开启 | → 超重 |
| 2022 年 8 月 24 日 | 277.36% | 奥本海默 | 26 美元 → 10 美元 | 维护 | 跑赢大盘 |
| 03/21/2022 | 881.13% | 奥本海默 | 32 美元 → 26 美元 | 维护 | 跑赢大盘 |
| 03/18/2022 | 881.13% | Craig-Hallum | 28 美元 → 26 美元 | 维护 | 买 |
| 11/24/2020 | 1032.08% | 贝伦贝格 | → 30 美元 | 启动覆盖范围开启 | → 购买 |
| 05/20/2020 | 1032.08% | Stifel | 25 美元 → 30 美元 | 维护 | 买 |
| 05/20/2020 | 1107.55% | 奥本海默 | 27 美元 → 32 美元 | 维护 | 跑赢大盘 |
| 2020 年 4 月 21 日 | 843.4% | Stifel | 21 美元 → 25 美元 | 维护 | 买 |
| 04/09/2020 | 692.45% | Stifel | → 21 美元 | 启动覆盖范围开启 | → 购买 |
| 03/06/2020 | 1032.08% | JMP 证券 | 22 美元 → 30 美元 | 维护 | 跑赢大盘 |
| 2020 年 2 月 25 日 | 918.87% | 奥本海默 | → 27 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 01/28/2020 | 881.13% | BTIG | → 26 美元 | 启动覆盖范围开启 | → 购买 |
| 01/22/2020 | 730.19% | JMP 证券 | → 22 美元 | 启动覆盖范围开启 | → 市场跑赢大盘 |
| 07/26/2019 | 390.57% | 贝尔德 | → 13 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for Cue Biopharma (CUE)?
Cue Biopharma（CUE）的目标价格是多少？
The latest price target for Cue Biopharma (NASDAQ: CUE) was reported by Piper Sandler on November 6, 2023. The analyst firm set a price target for $8.00 expecting CUE to rise to within 12 months (a possible 201.89% upside). 7 analyst firms have reported ratings in the last year.
派珀·桑德勒于2023年11月6日公布了Cue Biopharma（纳斯达克股票代码：CUE）的最新目标股价。该分析公司将目标股价定为8.00美元，预计CUE将在12个月内升至12个月内（可能上涨201.89％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Cue Biopharma (CUE)?
Cue Biopharma（CUE）的最新分析师评级是多少？
The latest analyst rating for Cue Biopharma (NASDAQ: CUE) was provided by Piper Sandler, and Cue Biopharma maintained their overweight rating.
派珀·桑德勒对Cue Biopharma（纳斯达克股票代码：CUE）的最新分析师评级由派珀·桑德勒提供，Cue Biopharma维持增持评级。
When is the next analyst rating going to be posted or updated for Cue Biopharma (CUE)?
Cue Biopharma（CUE）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cue Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cue Biopharma was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Cue Biopharma的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Cue Biopharma的最新评级是在2023年11月6日公布的，因此您应该预计下一个评级将在2024年11月6日左右公布。
Is the Analyst Rating Cue Biopharma (CUE) correct?
分析师对 Cue Biopharma（CUE）的评级是否正确？
While ratings are subjective and will change, the latest Cue Biopharma (CUE) rating was a maintained with a price target of $7.00 to $8.00. The current price Cue Biopharma (CUE) is trading at is $2.65, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Cue Biopharma（CUE）评级保持不变，目标股价为7.00美元至8.00美元。Cue Biopharma（CUE）目前的交易价格为2.65美元，超出了分析师的预期区间。